Cantor Fitzgerald resumed coverage on Regeneron Pharma with a new price target
$REGN
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald resumed coverage of Regeneron Pharma with a rating of Overweight and set a new price target of $695.00